| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high populationIncreasing DKK1 levels furt...
Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.
Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...